by dvcr23 | Sep 6, 2023 | Uncategorized
OVERLAND PARK, Kan.; September 6, 2023 – Dr. Vince Clinical Research (DVCR), a full-service clinical research organization (CRO), today announced the first dosing in Cingulate Therapeutics’ CTx-1301 Phase III dose-optimization onset and duration laboratory classroom...
by Salvador Solis | Aug 29, 2023 | Uncategorized
Strategic collaboration amplifies accessibility to Clario’s Early Precision QT (EPQT) methodology, enabling biopharmaceutical firms to secure more accurate and cost-efficient cardiac safety data in early clinical development stages. Meticulous multi-stage evaluation...
Recent Comments